SOURCE: AspenBio Pharma, Inc.

August 11, 2008 11:14 ET

AspenBio Pharma to Present at the Noble Financial Equity Conference

CASTLE ROCK, CO--(Marketwire - August 11, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the Fourth Annual Noble Financial Equity Conference to be held August 18-19 at the Loews Lake Las Vegas Resort, Nevada.

AspenBio president and CEO, Richard G. Donnelly, is scheduled to present on Monday, August 18 at 12:30 p.m. Pacific Time. The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides. Access is available by logging on to the conference website www.noblemadmax.com or by using the following link: http://hosted.mediasite.com/hosted4/Viewer/?peid=0c0c799c-d64a-403b-912a-31891ddb9f5b. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

Mr. Donnelly will discuss the continued advancement of AppyScore™, the world's first blood-based screening/triage test for human appendicitis. The company is conducting an 800 patient FDA clinical trial in preparation for a late 2008 FDA 510(k) filing. He will also discuss the exclusive license and commercialization agreement AspenBio recently signed with Novartis Animal Health, Inc. for the development and worldwide launch of AspenBio's novel bovine reproduction drugs, BoviPure LH™ and BoviPure FSH™.

About Noble Financial

Noble Financial is a privately held, full-service capital markets firm driven by what is often overlooked by other firms -- uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences -- 2008 marks their fourth annual -- allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 24 years and has offices in Florida, New York City and Boston.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use in animals of economic importance. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out acute appendicitis in patients complaining of abdominal pain. For more information, go to www.aspenbiopharma.com.

Forward-Looking Statements

This news release includes "forward-looking statements" of AspenBio Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including statements regarding the ability to successfully complete the development of, obtain FDA approval for, cost effectively manufacture and generate revenues from the appendicitis test as well as the animal products under this agreement and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.

Contact Information

  • For more information contact:
    AspenBio Pharma, Inc.
    Gregory Pusey
    Chairman
    Tel 303-722-4008

    Investor Relations
    Liolios Group, Inc.
    Scott Liolios or Ron Both
    Tel 949-574-3860